MEI Historical Income Statement

MEIP Stock

USD 2.55 0.15 5.56%

Historical analysis of MEI Pharma income statement accounts such as Gross Profit of 68.2 M can show how well MEI Pharma performed in making a profits. Evaluating MEI Pharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of MEI Pharma's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining MEI Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether MEI Pharma is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MEI Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in MEI Stock, please use our How to Invest in MEI Pharma guide.

About MEI Income Statement Analysis

MEI Pharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to MEI Pharma shareholders. The income statement also shows MEI investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

MEI Pharma Income Statement Chart

At this time, MEI Pharma's Income Before Tax is relatively stable compared to the past year. As of 12/16/2024, Net Income is likely to grow to about 18.7 M, while Total Operating Expenses is likely to drop slightly above 31.9 M.

Selling General Administrative Other Operating Expenses Research Development Net Income

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of MEI Pharma. It is also known as MEI Pharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in MEI Pharma financial statement analysis. It represents the amount of money remaining after all of MEI Pharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Most accounts from MEI Pharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into MEI Pharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MEI Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in MEI Stock, please use our How to Invest in MEI Pharma guide.At this time, MEI Pharma's Income Before Tax is relatively stable compared to the past year. As of 12/16/2024, Net Income is likely to grow to about 18.7 M, while Total Operating Expenses is likely to drop slightly above 31.9 M.

MEI Pharma income statement Correlations

	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Net Income	Income Tax Expense	Cost Of Revenue	Selling And Marketing Expenses	Total Other Income Expense Net	Depreciation And Amortization	Net Income From Continuing Ops	Non Operating Income Net Other	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation
Selling General Administrative		0.83	0.82	0.88	-0.37	-0.28	0.79	-0.25	0.88	-0.23	-0.21	0.13	0.12	-0.29	0.38	0.05	-0.21	0.61	0.06	0.69	0.64	0.89
Total Revenue	0.83		1.0	0.52	0.17	0.26	0.39	0.29	0.53	0.26	0.27	0.54	0.01	-0.08	0.12	0.21	0.28	0.52	-0.16	0.83	0.8	0.84
Gross Profit	0.82	1.0		0.51	0.18	0.27	0.38	0.31	0.52	0.27	0.28	0.55	-0.06	-0.06	0.12	0.24	0.28	0.52	-0.16	0.82	0.81	0.85
Other Operating Expenses	0.88	0.52	0.51		-0.74	-0.65	0.97	-0.61	1.0	-0.59	-0.57	-0.14	0.16	-0.37	0.49	-0.02	-0.58	0.48	0.28	0.31	0.3	0.75
Operating Income	-0.37	0.17	0.18	-0.74		0.97	-0.84	0.94	-0.74	0.89	0.87	0.55	-0.16	0.33	-0.5	0.21	0.89	-0.18	-0.46	0.28	0.27	-0.19
Ebit	-0.28	0.26	0.27	-0.65	0.97		-0.76	0.97	-0.65	0.81	0.8	0.62	-0.11	0.29	-0.58	0.23	0.81	-0.23	-0.39	0.36	0.31	-0.14
Research Development	0.79	0.39	0.38	0.97	-0.84	-0.76		-0.7	0.98	-0.69	-0.67	-0.22	0.11	-0.31	0.51	-0.01	-0.69	0.42	0.35	0.15	0.17	0.64
Ebitda	-0.25	0.29	0.31	-0.61	0.94	0.97	-0.7		-0.6	0.74	0.72	0.58	-0.21	0.29	-0.66	0.44	0.74	-0.3	-0.35	0.3	0.26	-0.07
Total Operating Expenses	0.88	0.53	0.52	1.0	-0.74	-0.65	0.98	-0.6		-0.59	-0.57	-0.14	0.11	-0.36	0.49	0.01	-0.58	0.49	0.27	0.31	0.31	0.76
Income Before Tax	-0.23	0.26	0.27	-0.59	0.89	0.81	-0.69	0.74	-0.59		1.0	0.63	-0.14	0.35	-0.05	-0.06	1.0	0.25	-0.39	0.37	0.43	-0.02
Net Income	-0.21	0.27	0.28	-0.57	0.87	0.8	-0.67	0.72	-0.57	1.0		0.64	-0.14	0.35	-0.01	-0.05	0.99	0.28	-0.3	0.37	0.43	0.01
Income Tax Expense	0.13	0.54	0.55	-0.14	0.55	0.62	-0.22	0.58	-0.14	0.63	0.64		-0.25	0.1	0.01	0.04	0.64	0.3	-0.15	0.43	0.4	0.22
Cost Of Revenue	0.12	0.01	-0.06	0.16	-0.16	-0.11	0.11	-0.21	0.11	-0.14	-0.14	-0.25		-0.2	0.09	-0.47	-0.12	-0.02	0.04	0.08	-0.08	-0.16
Selling And Marketing Expenses	-0.29	-0.08	-0.06	-0.37	0.33	0.29	-0.31	0.29	-0.36	0.35	0.35	0.1	-0.2		-0.06	0.08	0.28	-0.03	-0.07	-0.06	-0.01	-0.15
Total Other Income Expense Net	0.38	0.12	0.12	0.49	-0.5	-0.58	0.51	-0.66	0.49	-0.05	-0.01	0.01	0.09	-0.06		-0.56	-0.05	0.86	0.27	0.09	0.2	0.36
Depreciation And Amortization	0.05	0.21	0.24	-0.02	0.21	0.23	-0.01	0.44	0.01	-0.06	-0.05	0.04	-0.47	0.08	-0.56		-0.06	-0.4	0.01	-0.12	-0.13	0.24
Net Income From Continuing Ops	-0.21	0.28	0.28	-0.58	0.89	0.81	-0.69	0.74	-0.58	1.0	0.99	0.64	-0.12	0.28	-0.05	-0.06		0.25	-0.39	0.39	0.43	-0.02
Non Operating Income Net Other	0.61	0.52	0.52	0.48	-0.18	-0.23	0.42	-0.3	0.49	0.25	0.28	0.3	-0.02	-0.03	0.86	-0.4	0.25		0.08	0.55	0.6	0.65
Tax Provision	0.06	-0.16	-0.16	0.28	-0.46	-0.39	0.35	-0.35	0.27	-0.39	-0.3	-0.15	0.04	-0.07	0.27	0.01	-0.39	0.08		-0.28	-0.24	0.05
Interest Income	0.69	0.83	0.82	0.31	0.28	0.36	0.15	0.3	0.31	0.37	0.37	0.43	0.08	-0.06	0.09	-0.12	0.39	0.55	-0.28		0.91	0.65
Net Interest Income	0.64	0.8	0.81	0.3	0.27	0.31	0.17	0.26	0.31	0.43	0.43	0.4	-0.08	-0.01	0.2	-0.13	0.43	0.6	-0.24	0.91		0.67
Reconciled Depreciation	0.89	0.84	0.85	0.75	-0.19	-0.14	0.64	-0.07	0.76	-0.02	0.01	0.22	-0.16	-0.15	0.36	0.24	-0.02	0.65	0.05	0.65	0.67

Click cells to compare fundamentals

MEI Pharma Account Relationship Matchups

MEI Pharma income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	57.1M	44.3M	37.2M	284K	326.6K	310.3K
Selling General Administrative	16.7M	24.4M	30.5M	33.1M	23.3M	24.5M
Total Revenue	28.9M	25.5M	40.7M	48.8M	65.3M	68.6M
Gross Profit	26.2M	24.1M	39.5M	47.0M	64.9M	68.2M
Other Operating Expenses	53.5M	95.2M	116.2M	85.6M	50.8M	32.7M
Operating Income	(24.5M)	(69.7M)	(75.5M)	(36.8M)	14.5M	15.3M
Ebit	(1.7M)	(60.4M)	(76.4M)	(38.6M)	26.0M	27.3M
Research Development	34.1M	69.4M	85.6M	52.5M	16.6M	20.2M
Ebitda	(1.6M)	(60.1M)	(75.2M)	(36.8M)	26.4M	27.7M
Total Operating Expenses	50.8M	93.8M	116.2M	85.6M	50.8M	31.9M
Income Before Tax	(46.0M)	(50.6M)	(54.5M)	(31.8M)	17.8M	18.7M
Net Income	(46.0M)	(41.3M)	(54.5M)	(31.8M)	17.8M	18.7M
Cost Of Revenue	2.7M	1.4M	1.2M	1.8M	383K	363.9K
Total Other Income Expense Net	(21.5M)	19.1M	21.0M	4.9M	3.2M	4.6M
Depreciation And Amortization	109K	285K	1.2M	1.8M	383K	402.2K
Net Income From Continuing Ops	(46.0M)	(50.6M)	(54.5M)	(31.8M)	17.8M	18.7M
Non Operating Income Net Other	(9.1M)	29.4M	(21.5M)	19.1M	22.0M	23.1M
Net Income Applicable To Common Shares	(46.0M)	(50.6M)	(54.5M)	(31.8M)	(28.7M)	(30.1M)
Interest Income	1.4M	510K	284K	3.3M	3.3M	3.4M
Net Interest Income	1.4M	510K	284K	3.3M	3.3M	3.4M
Reconciled Depreciation	109K	285K	326K	386K	383K	234.7K

Pair Trading with MEI Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MEI Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MEI Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against MEI Stock

0.55	FLGC	Flora Growth Corp	Pair Corr
0.37	DYAI	Dyadic International	Pair Corr
0.35	DNA	Ginkgo Bioworks Holdings	Pair Corr
0.32	ESPR	Esperion Therapeutics	Pair Corr
0.32	IMAB	I Mab	Pair Corr

The ability to find closely correlated positions to MEI Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MEI Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MEI Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MEI Pharma to buy it.

The correlation of MEI Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MEI Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MEI Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for MEI Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for MEI Stock Analysis

When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

MEI Historical Income Statement

About MEI Income Statement Analysis

MEI Pharma Income Statement Chart

Other Operating Expenses

Net Income

MEI Pharma income statement Correlations

MEI Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

MEI Pharma income statement Accounts

Pair Trading with MEI Pharma

Moving against MEI Stock

Additional Tools for MEI Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Total Operating Expenses	+ 1.0	Other Operating Expenses
Net Income	+ 1.0	Income Before Tax
Net Income From Continuing Ops	+ 1.0	Income Before Tax
Net Income From Continuing Ops	+ 0.99	Net Income
Total Operating Expenses	+ 0.98	Research Development

Research Development	- 0.84	Operating Income
Research Development	- 0.76	Ebit
Total Operating Expenses	- 0.74	Operating Income
Operating Income	- 0.74	Other Operating Expenses
Ebitda	- 0.7	Research Development
Net Income From Continuing Ops	- 0.69	Research Development